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Abstract
Background and purpose: The incidence of cardiovascular events remains high in patients with myocardial
infarction (MI) despite advances in current therapies. New and better methods for identifying patients at high risk of
recurrent cardiovascular (CV) events are needed. This study aimed to analyze the predictive value of an oral glucose
tolerance test (OGTT) in patients with acute myocardial infarction without known diabetes mellitus (DM).
Methods: The prospective cohort study consisted of 123 men and women aged between 31–80 years who had
suffered a previous MI 3–12 months before the examinations. The exclusion criteria were known diabetes mellitus.
Patients were followed up over 6.03 ± 1.36 years for CV death, recurrent MI, stroke and unstable angina pectoris.
A standard OGTT was performed at baseline.
Results: 2-h plasma glucose (HR, 1.27, 95% CI, 1.00 to 1.62; P < 0.05) and smoking (HR, 3.56, 95% CI, 1.02 to 12.38;
P < 0.05) proved to be independent predictors of CV events in multivariate statistical analysis after adjustments for
age, sex, total cholesterol, and other baseline characteristics.
Conclusions: In this study population, with previous MI and without known DM, 2-h PG and smoking were
significant predictors of CV death, recurrent MI, stroke and unstable angina pectoris, independent of baseline
characteristics and medical treatment.
Introduction
Previous studies have shown that almost two thirds of
patients with cardiovascular disease suffer from abnor-
mal glucose metabolism [1,2]. The majority of these
cases are not detected by fasting plasma glucose (FPG)
but with 2-h PG after OGTT [1,3]. There is evidence
that postprandial hyperglycemia is an independent risk
factor for atherosclerosis and has an even greater effect
than fasting plasma glucose [4,5] on future events.
The pathophysiology behind the association between
postprandial hyperglycemia and atherosclerosis is not
fully understood. Our research group has previously
reported a correlation between 2-h PG and inflammation
parameters in patients with coronary artery disease
(CAD) [4].
According to current understanding, hyperglycemia
induces oxidative stress which, in combination with sol-
uble advanced glycation end products (AGEs) and lipid
peroxidation products leads to endothelial dysfunction
and expression of inflammatory genes [6-8].
The purpose of this study was to analyze the predictive
value of an OGTT in patients with acute myocardial in-
farction (AMI) without known DM after several years of
follow-up.
Methods
Subjects
123 patients, men and women aged between 31–80 years
with a previous acute MI, took part in the study. The in-
clusion criterion was hospital-diagnosed myocardial in-
farction that had occurred 3–12 months before the
examinations. The patients were recruited from the de-
partment of Cardiology at Karolinska University Hos-
pital Huddinge, Sweden. 90% of the participants were
examined within three months of the MI. We chose
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three months to ensure the examination took place
when patients were in a clinically stable condition. All
patients who were admitted to the cardiac intensive care
unit because of acute myocardial infarction were in-
cluded in the study, consecutively, throughout the period
2002–2003. The exclusion criteria were known diabetes
mellitus and chronic inflammatory disease. Blood sam-
ples had been taken for the control of inflammatory factors
in another study. All subjects gave informed consent
after written and oral information.
The Karolinska Institute ethics committee at Karolinska
University Hospital Huddinge approved the study. All of
the patients except five (who had moved to another city)
were followed up at our outpatient clinic every six
months and all CV events were recorded in a case report
form (CRF). The five patients who had moved were tele-
phoned for a clinical check-up every six months.
Acute MI was defined using the criteria of the European
Society of Cardiology and the American College of Cardiology
[9].
Follow-up and cardiovascular events
All patients were followed up over 6.03 ± 1.36 years. The
primary end point was defined as any of the following:
death from any cause, nonfatal reinfarction or stroke,
unstable angina pectoris, congestive heart failure requir-
ing hospitalization, and coronary revascularization pro-
cedure (percutaneous coronary angioplasty or coronary
artery bypass grafting). Time to first event was used as
the endpoint. When revascularization procedures oc-
curred during AMI or unstable angina, it was recorded
as a single event (e.g. AMI treated with primary percu-
taneous angioplasty was recorded as AMI. A peripheral
vascular event was defined as any increase in peripheral
ischemic symptoms resulting in any peripheral revascu-
larization procedure (percutaneous transluminal angio-
plasty or operation). The absence of any of these features
was considered as event-free survival.
Measurements
Venous blood was drawn after an overnight fast and five
min of supine rest, to determine the plasma glucose and
plasma levels of cholesterol and triglycerides using
established methods. Plasma glucose concentrations at 0
and 120 min following ingestion of 75 g glucose were
analyzed, using glucose oxidase technique on a Hitachi
917 system. DM and impaired glucose tolerance (IGT)
were defined based on American Diabetes Association
(ADA) definitions [10]. On the basis of 2-h PG alone,
individuals were classified into categories of newly diag-
nosed diabetes, IGT and normal glucose tolerance
(NGT) if their 2-h PG concentrations were≥11.1, 7.8–11.0
and < 7.8 mmol/l, respectively.
Resting blood pressure was measured in the right arm
after about 10 min of supine rest. Body mass index
(BMI) was measured according to recommended princi-
ples. Smoking was assessed by a questionnaire.
Echocardiography
All patients underwent a standard echocardiographic
evaluation, using a 2.5 MHz transducer (System Five, GE
Vingmed, Horten, Norway). The echocardiographic studies
were performed with the subject in supine left lateral de-
cubitus, after 30 minutes of rest. One physician recorded
all the echocardiograms. Two-dimensional imaging of
the longitudinal parasternal view was checked in order
to avoid angulation of the ultrasonic beam, and conse-
quent changes in the left ventricular shape. Left ven-
tricular internal dimension, left ventricular posterior
wall and interventricular septum thickness were mea-
sured, according to the recommendations of the Ameri-
can Society of Echocardiography [11]. The ejection fraction
was calculated according to Simpson’s formula.
Statistical analysis
Results are presented as means and standard deviations
of the mean. All data analyses were done using Statistica
for Windows software version 10.0. Mann–Whitney U test
and X² test were performed. The Cox regression model
was used to identify the predictive factors.
Results
Table 1 shows the baseline characteristics of the study
patients. There were no significant differences between the
patients with CV events compared with those without CV
events regarding known risk factors such as hypertension,
smoking habits, cholesterol value, LVEF and current medi-
cation. During the follow-up at 6.03±1.36 years, CV events
had occurred in 30 patients. Figure 1 shows the distribution
of the various CV events in the patients.
Table 2 shows previous interventions and medical treat-
ment in the study population. Coronary angiography was
performed in 92 patients. That showed one vessel disease
in 37 patients, two vessel diseases in 15 patients and 3 ves-
sel diseases in 22 patients. In 16 cases no significant coron-
ary artery stenosis was identified.
Table 3 shows baseline characteristics of the subjects with
DM, IGT and NGT. We found no statistically significant
difference between the three groups with DM, IGT and
NGT for the occurrence of CV events.
Table 4 shows the Cox proportional-hazards regression
model with the primary end point as outcome for some im-
portant baseline variables. In this study we have only ana-
lyzed triglycerides and total cholesterol. Both these and
BMI were entered in Cox proportional-hazards regression
model, but they showed no significant predictive value.
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In multivariate statistical analysis and after adjustment
for age, sex, total cholesterol, and other baseline character-
istics, 2-h plasma glucose (HR, 1.27, 95% CI, 1.00 to 1.62;
P <0.05) and smoking (HR, 3.56, 95% CI, 1.02 to 12.38;
P <0.05) remained as independent predictors of CV events.
Discussion
During the six-year follow-up, the incidence of cardiovascu-
lar events after myocardial infarction was 24%. Smoking
and 2-h PG were two independent predictors of CV in
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Figure 1 Distribution of the various CV events in the patients with CV events. AP= angina pectoris, CV= cardiovascular event, MI=
myocardial infarction. PCI= percutaneous coronary intervention, CABG= coronary artery bypass grafting.
Table 1 Baseline characteristics
Subjects with
CV event
n = 30
Subjects without
CV event
n = 93
Age (years) 62 ± 12 61 ± 10
Gender 23 (77) 71 (76)
- Male, n (%) 7 (23) 22 (24)
- Female, n (%)
Smoking habits 6 (20) 14 (15)
- Yes, n (%) 4 (14) 24 (26)
- Never, n (%) 19 (63) 52 (56)
- Prior smoker, n (%) 1 (3) 3 (3)
- Moist snuff, n (%)
BMI (kg/m2) 27 ± 4 27 ± 4
Systolic blood pressure (mmHg) 135 ± 21 138 ± 20
Diastolic blood pressure (mmHg) 77 ± 9 80 ± 9
Triglycerides, mmol/l (mean±SD) 1.7 ± 1.0 1.6 ± 1.0
Total cholesterol, mmol/l (mean±SD) 4.2 ± 0.7 4.1 ± 0.7
Heart rate, beats/min (mean±SD) 61 ± 11 58 ± 9
Fasting plasma glucose (mmol/l) 5.5 ± 1.7 5.4 ± 1.1
2-h plasma glucose (mmol/l) 8.1 ± 3.3⪵ 7.5 ± 3.0
Ejection fraction (%) 49 ± 11 54 ± 7.0
*P<0.05 Mann Whitney test.
Table 2 Interventions and treatment in the study group
(n=123)
Interventions All subjects
(n=123)
Subjects with
CV events
(n=30)
Subjects without
CV events
(n=93)
Previous PCI, n (%) 58 (47) 13 (43) 45 (48)
Previous CABG, n (%) 20 (16) 6 (20) 14 (15)
Thrombolysis, n (%) 18 (15) 3 (10) 15 (16)
Drugtreatment
Aspirin, n (%) 122 (99) 30 (100) 92 (99)
Betablocker, n (%) 111 (90) 25 (83) 86 (92)
ACE inhibitor, n (%) 31 (25) 10 (33) 21 (23)
Statin, n (%) 111 (90) 28 (93) 83 (94)
PCI= percutaneus coronary intervention. CABG= Coronary artery by-pass
grafting.
ACE= angiotensin-converting enzyme. CV= Cardiovascular event.
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patients with myocardial infarction. Our research group
has previously reported that the prevalence of IGT and un-
known DM is high in patients with ischemic heart disease
[1]. This study confirms the results from previous studies
[12,13] and highlights the clinical relevance of hypergly-
cemia 2-h post glucose challenge as independent risk fac-
tors for CV events in patients with ischemic heart disease.
Several epidemiological studies have indicated that patients
with pre-diabetic conditions, below the threshold for dia-
betes, are at higher risk for cardiovascular disease [14,15].
Thus, previous studies have shown that IGT and newly de-
tected diabetes were risk factors for increased CV events
after AMI [16,17]. However, it's still unclear whether
patients with 2-h postchallenge glucose below the threshold
for DM after MI are at a higher risk of CV events. This
study also suggests, in line with previous reports [18,19]
that 2-h PG is a better risk predictor of CV events than
FPG.
Concurring with our study, Schinner et al. [20] found
a high prevalence of impaired glucose metabolism in
patients with coronary heart disease (CHD) assessed by
coronary angiography. They found a continuous increased
risk of CHD with blood glucose levels even in the sub-
diabetic range. However, as in our study, they found that
post-prandial hyperglycaemia contributed more to CHD
than fasting hyperglycemia.
The pathophysiological mechanism behind the rela-
tionship between 2-h plasma glucose and CV events is
not fully understood. Previous studies have shown that
there is a correlation between 2-h plasma glucose with
higher levels of plasminogen activator inhibitor (PAI)
[21] and high sensitive C-reactive protein as a marker
for low grade inflammation [4]. In line with our study,
Chu et al. [22] showed that postchallenge hyperglycemia,
increased levels of pro-inflammatory markers such as
tumor necrosis factor alpha (TNF-α) and nitrotyrosone
time-dependently, and that these levels were associated
with coronary artery disease (CAD) in patients without
previous recognized diabetes.
Disturbed glucose metabolism is associated with left
ventricular dysfunction and increased intima media
thickness of the carotid artery [23]. Patients with IGT
often develop metabolic syndrome with increased obesity.
Thus the pathophysiological relationship between 2-h
plasma glucose and CV events may be explained by dif-
ferent mechanisms.
Other investigators have suggested age, left ventricular
ejection fraction, use of beta-blockers, aspirin and statins
as potential predictors for long-term CV inpatients with
AMI [24-27] But even after adjustment for pharmaco-
logical therapy, age and other proposed predictors, we
found that 2-h post load PG and smoking were inde-
pendent predictors of CV events following AMI. The
observation that smoking predicts CV disease is in line
with previous studies [28,29].
Smoking is an independent risk factor for all-cause
mortality and cardiovascular death and is also associated
with impaired glucose tolerance and increased risk of
type 2 diabetes [30,31]. The pathophysiological mechan-
ism by which smoking effects glucose intolerance and
worsens clinical outcomes in diabetic patients is not fully
Table 3 Characteristics of the subjects with DM, IGT
and NGT
DM
(n = 13)
IGT
(n = 29)
NGT
(n = 68)
Famle 3 (23%) 6 (21%) 18 (26%)
Age (year) 61 ± 11 65 ± 8* 60 ± 12
BMI (kg/m2) 29 ± 3† 27 ± 4 26 ± 3
Triglycerides (mmol/l) 2.7 ± 1.1†,} 1.8 ± 1.3 1.4 ± 0.7
Cholestrol (mmol/l) 4.9 ± 1.1 4.6 ± 0.8 4.6 ± 1.1
FPG (mmol/l) 7.7 ± 2.6†,} 5.4 ± 0.6* 4.9 ± 0.5
2-h PG (mmol/l) 14.4 ± 3.4†,} 9.2 ± 0.90* 5.8 ± 1.0
Systolic blood pressure (mmHg) 146 ± 25† 146 ± 20* 133 ± 19
Diastolic blood pressure (mmHg) 79 ± 11 82 ± 10* 78 ± 9
Cardiovascular events, n(%) 3 (23) 8 (27) 19 (28)
DM, diabetes mellitus; IGT, impaired glucose tolerance; NGT, normal glucose
tolerance.
† DM vs. NGT; P < 0.05.
* IGT vs. NGT; P < 0.05.
} DM vs. IGT; p<0.05.
Table 4 Cox proportional-hazards regressions model with primary end point as outcome, including all important
baseline variables
Age-and gender adjusted Cox regressions Univariate logistic regression
B (SE) HR (95% CI) P value B (SE) OR (95% CI) P value
Age (years) 0.03 (0.03) 1.03 (0.96-1.10) 0.38 0.01 (0.03) 1.01 (0.96-1.07) 0.66
Systolic BP mmHg 0.02 (0.65) 1.02 (0.29-3.63) 0.98 -0.25 (0.65) 0.78 (0.22-2.78) 0.70
Fasting PG mmol/l −0.81 (0.47) 0.44 (0.18–1.11) 0.08 -0.27 (0.37) 1.31 (0.37-1.59) 0.47
2h PG mmol/l 0.25 (0.12) 1.27 (1.00-1.62) 0.04 0.08 (0.09) 1.08 (0.91-1.29) 0.38
Smoking 1.27 (0.64) 3.56 (1.02-12.38) 0.04 1.34 (0.62) 3.83 (1.14-12.85) 0.03
Sex 0.12 (0.33) 1.27 (0.35-4.66) 0.72 0.03 (0.70) 1.03 (0.26-4.09) 0.96
BP= blood pressure, PG= plasma glucose, HR= hazard ratio, OR= odds ratio.
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understood. According to previous studies, smoking leads
to increased insulin resistance, beta cell dysfunction,
endothelial dysfunction and low-grade chronic inflam-
mation [32].
Systolic blood pressure was also associated with the
CV events; however, the relationship was significant only
in univariate analysis. Previous studies have shown a cor-
relation between high blood pressure and metabolic
changes, such as impaired glucose tolerance and post-
challenge hyperglycemia. The exact mechanism of this
correlation remains somewhat unclear. It has been dem-
onstrated that postprandial hyperglycemia is associated
with increased oxidative stress [33,34] and endothelial
dysfunction [35,36] and this would promote the develop-
ment of atherosclerosis [36] and hypertension [36,37].
Furthermore, hyperglycemia is related to decreased blood
flow to skeletal muscle, resulting in decreased glucose
utilization [38].
Study limitations
This study consisted of a small number of patients in
a single center. Thus, despite a seemingly convincing
message, our results may not reflect the real world
population.
In conclusion, we show that in this study population
with previous MI without known DM, 2-h plasma glu-
cose and smoking were significant predictors of CV
death, recurrent MI, stroke and unstable angina pectoris,
independent of baseline characteristics and medical
treatment.
Clinical implication
Our results suggest that 2-h PG and smoking could be
linked to an increased risk of CV events in patients with
previous MI. An OGTTcould be added to the standard
risk evaluation procedures in a hospital settings, as a po-
tential method for preventing CV events it could be the
focus of future clinical investigations.
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